No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ETNB 89bio
- 7.600
- -0.160-2.06%
Close Jul 2 16:00 ET
- 7.880
- +0.280+3.68%
Post 19:35 ET
747.72MMarket Cap-3800P/E (TTM)
7.850High7.410Low916.37KVolume7.850Open7.760Pre Close6.92MTurnover1.31%Turnover RatioLossP/E (Static)98.38MShares19.61052wk High1.46P/B530.46MFloat Cap6.57552wk Low--Dividend TTM69.80MShs Float47.253Historical High--Div YieldTTM5.67%Amplitude2.000Historical Low7.555Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | 89Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PDF Version SAN FRANCISCO, June 14, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and com
89bio Up Over 12%, on Pace for Largest Percent Increase Since March 2023 -- Data Talk
89bio Inc ( ETNB ) is currently at $9.76, up $1.08 or 12.44% --Would be highest close since April 12, 2024, when it closed at $9.82 --On pace for largest percent increase since March 23, 2023, when
Express News | Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price Target
89bio Price Target Maintained With a $29.00/Share by HC Wainwright & Co.
89bio Price Target Maintained With a $29.00/Share by HC Wainwright & Co.
H.C. Wainwright Maintains 89bio(ETNB.US) With Buy Rating, Maintains Target Price $29
H.C. Wainwright analyst Ed Arce maintains $89bio(ETNB.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 40.0% and a total aver
Comments
» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
7
$89bio(ETNB.US$
NEWS
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
89bio has initiated the Phase 3 ENLIGHTEN-Cirrhosis trial for pegozafermin in patients with MASH and compensated cirrhosis (F4). This is the first FGF21 analog to reach this trial stage for this patient subset. The trial will involve 760 patients, assessing fibrosis regression at 24 months, potentially supporting ac...
NEWS
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
89bio has initiated the Phase 3 ENLIGHTEN-Cirrhosis trial for pegozafermin in patients with MASH and compensated cirrhosis (F4). This is the first FGF21 analog to reach this trial stage for this patient subset. The trial will involve 760 patients, assessing fibrosis regression at 24 months, potentially supporting ac...
$89bio(ETNB.US$ 💀hope the strong buy suggestions promoter goto jail for fraud😭
According to Vantage market estimates for NASH could cross 100 Billion by 2030
NASH Basket- $Madrigal Pharmaceuticals(MDGL.US$ $Viking Therapeutics(VKTX.US$ $Akero Therapeutics(AKRO.US$ $89bio(ETNB.US$
Than we already know how big Obesity market is going to be over next decade with global 1.5 Billion obese pts
Obesity Basket $Viking Therapeutics(VKTX.US$ $Eli Lilly and Co(LLY.US$ $Novo-Nordisk A/S(NVO.US$
NASH Basket- $Madrigal Pharmaceuticals(MDGL.US$ $Viking Therapeutics(VKTX.US$ $Akero Therapeutics(AKRO.US$ $89bio(ETNB.US$
Than we already know how big Obesity market is going to be over next decade with global 1.5 Billion obese pts
Obesity Basket $Viking Therapeutics(VKTX.US$ $Eli Lilly and Co(LLY.US$ $Novo-Nordisk A/S(NVO.US$
7
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg